Targeted therapies focus on specific molecular pathways dysregulated in glioblastoma, including inhibitors targeting EGFR and VEGF pathways, as well as PI3K pathway modulators [3,4,8,12,13,15]. This evidence concerns the gene EGFR and glioblastoma.